Diabetes: Insulin plus metformin for T2DM-are there benefits?

Nature Reviews Endocrinology

Volumn 8, Issue 8, 2012, Pages 449-450

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PLACEBO;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG MECHANISM; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; TREATMENT OUTCOME;

EID: 84864283941     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.106     Document Type: Review

References (10)

1. Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577-1596 (2012).
2. Hemmingsen, B. et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ http://dx.doi.org/10.1136/bmj. e1771.
3. Bailey, C. J. et al. in Metformin, the Gold Standard. A scientific handbook. (ed. Bailey, C. J. et al.) 1-288 (Wiley, Chichester, 2007)
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
5. Johnson, J. A., Simpson, S. H., Toth, E. L. & Majumdar S. R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Med. 22, 497-502 (2005).
6. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
7. Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32, 187-192 (2009).
8. Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616-625 (2009).
9. Zhang, B. B., Zhou, G. & Li, C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407-416 (2009).
10. Bailey, C. J. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc. Drugs Ther. 22, 215-224 (2008).